Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook

Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue

November 6, 2018 4:15 PM EST

Total revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over 2017Diluted earnings per share (GAAP) of $0.52, a 79% increase over 2017Data from first three Phase III SPN-812 trials expected in December 2018Acquisition of Biscayne Neurotherapeutics, Inc. closed in October 2018Ranked #1 fastest growing pharmaceutical company worldwide per Fortune 100 fastest growing companies

ROCKVILLE, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for... More